|
Novabay Pharmaceuticals Inc (NYSE: NBY) |
|
Novabay Pharmaceuticals Inc
NBY's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Novabay Pharmaceuticals Inc 's sales fell
by -40.49 % in IV. Quarter 2024 from the same quarter a year ago.
Ranking at No. 1993
Major Pharmaceutical Preparations industry recorded
growth of revenues by 11.85 %
Novabay Pharmaceuticals Inc net loss decreased from $-5 millions, to $-1 millions in IV. Quarter 2024,
• More on NBY's Growth
|
|
Novabay Pharmaceuticals Inc realized a net loss in trailing twelve months.
Novabay Pharmaceuticals Inc realized cash reduction of $ -0.79 per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 0.21.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.1.
• More on NBY's Valuation
|
|
|
|
|
Novabay Pharmaceuticals Inc realized net loss in trailing twelve months.
Novabay Pharmaceuticals Inc realized cash outflow of $ -0.79per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 0.21.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.1.
• More on NBY's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com